



US009763885B2

(12) **United States Patent**
Dias

(10) **Patent No.:** **US 9,763,885 B2**
(45) **Date of Patent:** **Sep. 19, 2017**

(54) **ORAL TABLET FORMULATION
CONSISTING OF FIXED COMBINATION OF
ROSUVASTATIN AND EZETIMIBE FOR
TREATMENT OF HYPERLIPIDEMIA AND
CARDIOVASCULAR DISEASES**

(71) Applicant: **Althera Laboratories Ltd.**, Dublin (IE)

(72) Inventor: **Marie Charmaine Dias**, Morristown,
NJ (US)

(73) Assignee: **Althera Laboratories Ltd.**, Dublin (IE)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/350,905**

(22) PCT Filed: **May 1, 2013**

(86) PCT No.: **PCT/US2013/039018**

§ 371 (c)(1),
(2) Date: **Apr. 10, 2014**

(87) PCT Pub. No.: **WO2013/166117**

PCT Pub. Date: **Nov. 7, 2013**

(65) **Prior Publication Data**

US 2014/0287042 A1 Sep. 25, 2014

Related U.S. Application Data

(60) Provisional application No. 61/641,013, filed on May
1, 2012.

(51) **Int. Cl.**

A61K 9/00 (2006.01)

A61K 9/20 (2006.01)

A61K 31/397 (2006.01)

A61K 31/505 (2006.01)

A61K 9/24 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 9/2086** (2013.01); **A61K 9/2009**
(2013.01); **A61K 9/209** (2013.01); **A61K**
9/2018 (2013.01); **A61K 9/2027** (2013.01);
A61K 9/2054 (2013.01); **A61K 31/397**
(2013.01); **A61K 31/505** (2013.01)

(58) **Field of Classification Search**

CPC **A61K 2300/00**; **A61K 31/397**; **A61K**
31/505; **A61K 9/2009**; **A61K 9/2018**;
A61K 9/2027; **A61K 9/2054**; **A61K**
9/2086; **A61K 9/209**

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2003/0072800 A1 4/2003 Singh et al.
2004/0126423 A1* 7/2004 Moore et al. 424/465
2010/0204195 A1* 8/2010 Lulla et al. 514/210.02
2010/0247645 A1* 9/2010 Curdy et al. 424/468
2011/0262497 A1* 10/2011 Injac et al. 424/400

FOREIGN PATENT DOCUMENTS

EP 2233133 A1* 9/2010
WO 2009/024889 A2 2/2009
WO WO 2009024889 A2* 2/2009
WO 2010/021608 A1 2/2010
WO 2011/019326 A2 2/2011
WO 2011/139256 A2 11/2011
WO 2011/139256 A3 11/2011
WO 2012/064307 A1 5/2012
WO WO 2013066279 A1* 5/2013

OTHER PUBLICATIONS

PCT International Search Report and Written Opinion, Sep. 20,
2013.

PCT Notification Concerning Transmittal of International Prelimi-
nary report on Patentability, Nov. 13, 2014.

European Patent Office Supplementary European Search Report for
EP13785009.5 dated Nov. 27, 2015.

* cited by examiner

Primary Examiner — Robert A Wax

Assistant Examiner — Olga V Tcherkasskaya

(74) *Attorney, Agent, or Firm* — Berggren, Inc.

(57) **ABSTRACT**

The present invention is an orally consumed fixed combi-
nation formulation of both rosuvastatin and ezetimibe in one
tablet that is expected to have the same Area Under Curve
as two active ingredients taken together individually orally,
and pharmaceutically acceptable additives suitable for the
preparation. In preferred embodiments of this invention, the
rosuvastatin is in the form of rosuvastatin calcium and the
pharmaceutically acceptable additives are selected from
diluents, disintegrants, glidants, lubricants, colorants and
combinations thereof.

9 Claims, 1 Drawing Sheet